search
Back to results

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Primary Purpose

Active Ankylosing Spondylitis

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
VC005 tablets
Tofacitinib Citrate Tablets
VC005 Tablets Placebo
Sponsored by
Jiangsu vcare pharmaceutical technology co., LTD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Active Ankylosing Spondylitis

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol; The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender; The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis (AS can be diagnosed by having Article ④ and any one of Articles ① to ③): ① lower back pain lasting for at least 3 months, with pain improving with activity but not with rest; ② limited movement of the lumbar spine in the anterior-posterior and lateral flexion directions; ③ thoracic extension less than normal for the same age and sex; ④ bilateral sacroiliac arthritis grade II-IV, or unilateral sacroiliac arthritis grade III-IV; The subject had active disease prior to the screening visit and randomization, defined as follows: Bath AS Disease Activity Index (BASDAI) score ≥ 4 and a spinal pain score (BASDAI question 2) ≥ 4 (see Annex 6 for scoring criteria); Subjects who have been treated with non-steroidal anti-inflammatory drugs (NSAIDs) and still have active disease, or who have discontinued NSAIDs due to intolerance; defined as follows: subjects must have had at least 2 cumulative inadequate clinical responses to the recommended dose (≥2 weeks of each NSAID and ≥4 weeks of total use) or intolerance to at least 2 different oral NSAIDs. Intolerance defined as discontinuation of treatment with NSAIDs due to associated adverse events (e.g., allergic reactions, gastrointestinal signs or symptoms, etc.); Subjects taking treatment with NASIDs at the time of screening, requiring stable dose continuation for ≥ 2 weeks prior to randomization; no change in drug dose during the study period except for emergencies; if not taking, discontinuation for at least ≥ 2 weeks prior to randomization; If subjects are enrolled in the study on a combination of methotrexate (MTX), salazosulfapyridine (SASP) and/or hydroxychloroquine (HCQ), subjects must receive a stable dose of MTX (≤25 mg/week) and/or SASP (≤3 g/day) and/or HCQ (≤400 mg/day) for at least 28 days prior to the baseline visit. A maximum of two background csDMARDs allowed in combination; Subjects taking oral glucocorticoids at screening at doses ≤10 mg/day of prednisone (or equivalent doses of other glucocorticoids) that need to be continued for ≥4 weeks prior to randomization; if subjects are not taking oral glucocorticoids, they need to be off them for at least ≥4 weeks prior to randomization; The subject has received ≤ 1 prior treatment with a biologic agent prior to randomization. Subjects previously treated with biologic agents must have been off ≥ 6 half-lives prior to randomization. Exclusion Criteria: 1. Presence of the following diseases or history of disease: A known or suspected history of complete spinal ankylosis, or clinically and imaging confirmed complete spinal ankylosis; A history of any other autoimmune rheumatic disease; Patients with a combination of severe extra-articular manifestations, such as hyperthermia, interstitial pneumonia, pleurisy, pericarditis, severe vasculitis, or neurological pathology; Patients with current or recent serious, or progressive, or uncontrolled disease, including: hepatic, renal, hematologic, gastrointestinal, endocrine, metabolic, respiratory, cardiovascular, or neurologic disease; or patients who, in the opinion of the investigator, may affect patient safety or compliance;etc. 2.Any of the following laboratory test indicators are met at the time of the screening test: Those who test positive for the following bacteria or viruses at screening, such as HIV, syphilis, Hepatitis B Virus (HBSAg, HBeAg, Hepatitis B Virus-DNA, anyone positive for any of the three), Hepatitis C Virus (positive for anti-Hepatitis C Virus antibodies); If screening stage hepatitis B surface antigen negative (HBsAg-) and anti-hepatitis B core antibody positive (HBcAb+), additional quantitative Hepatitis B Virus-DNA test is required and excluded if quantitative > normal value; Routine blood count: white blood cell count (WBC) <3×109/L, absolute neutrophil count (ANC) <1.5×109/L, absolute lymphocyte count (ALC) <0.8×109/L, platelets (PLT) <100×109/L, hemoglobin (Hb) <100 g/L;etc. 3. Is taking or has a history of taking medication that: Those who are receiving any other csDMARDs or biologic DMARDs (except MTX, SASP, HCQ in the inclusion criteria) or other prohibited concomitant medications; if previous use of csDMARDs such as thalidomide, hydroxychloroquine or leflunomide, those who discontinued thalidomide, hydroxychloroquine, etc. for ≤ 4 weeks and leflunomide for ≤ 8 weeks prior to randomization (using criteria subjects not more than 28 days after Kauleenamine treatment or active carbon elution were not allowed to be enrolled in the trial); Those who have been treated with any tyrosine kinase (JAK) inhibitor (e.g. Tofacitinib, Baricitinib, Upadacitinib, etc.);etc. 4. Those who may be allergic to VC005, similar drugs or their excipients 5. Those with substance abuse or alcohol dependence 6. Subjects who, in the opinion of the investigator, may be at risk of gastrointestinal perforation during the course of the trial 7. Those who have participated in a clinical trial with any drug or device within 12 weeks prior to screening and have used that drug or device 8. Subjects who have a history of major surgery, joint surgery within 6 months prior to screening or who are scheduled to have surgery during the trial 9. Female patients who are planning to become pregnant or who are pregnant or breastfeeding, or who are unable to use effective contraception throughout the trial and for 3 months after the end of the trial (see Appendix 14 for details) 10. Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.

Sites / Locations

  • Peking University People's HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Placebo Comparator

Arm Label

VC005 Tablets Low Dose groups

VC005 Tablets Medium Dose groups

VC005 Tablets High Dose groups

Tofacitinib Citrate Tablets groups

VC005 Tablets Placebo groups

Arm Description

Outcomes

Primary Outcome Measures

Percentage of patients achieving ASAS20
Percentage of patients achieving an Assessment of disease activity (signs and symptoms) in ankylosing spondylitis 20% improvement (ASAS20) in response at week 12 of treatment.

Secondary Outcome Measures

Full Information

First Posted
April 4, 2023
Last Updated
August 11, 2023
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
search

1. Study Identification

Unique Protocol Identification Number
NCT05814939
Brief Title
Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Official Title
A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 26, 2023 (Actual)
Primary Completion Date
April 23, 2026 (Anticipated)
Study Completion Date
April 23, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu vcare pharmaceutical technology co., LTD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Active Ankylosing Spondylitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Sequential Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
VC005 Tablets Low Dose groups
Arm Type
Experimental
Arm Title
VC005 Tablets Medium Dose groups
Arm Type
Experimental
Arm Title
VC005 Tablets High Dose groups
Arm Type
Experimental
Arm Title
Tofacitinib Citrate Tablets groups
Arm Type
Active Comparator
Arm Title
VC005 Tablets Placebo groups
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
VC005 tablets
Intervention Description
VC005 groups repeat administration for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Tofacitinib Citrate Tablets
Intervention Description
Tofacitinib Citrate groups repeat administration for 12 weeks
Intervention Type
Drug
Intervention Name(s)
VC005 Tablets Placebo
Intervention Description
VC005 placebo groups repeat administration for 12 weeks
Primary Outcome Measure Information:
Title
Percentage of patients achieving ASAS20
Description
Percentage of patients achieving an Assessment of disease activity (signs and symptoms) in ankylosing spondylitis 20% improvement (ASAS20) in response at week 12 of treatment.
Time Frame
Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol; The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender; The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis (AS can be diagnosed by having Article ④ and any one of Articles ① to ③): ① lower back pain lasting for at least 3 months, with pain improving with activity but not with rest; ② limited movement of the lumbar spine in the anterior-posterior and lateral flexion directions; ③ thoracic extension less than normal for the same age and sex; ④ bilateral sacroiliac arthritis grade II-IV, or unilateral sacroiliac arthritis grade III-IV; The subject had active disease prior to the screening visit and randomization, defined as follows: Bath AS Disease Activity Index (BASDAI) score ≥ 4 and a spinal pain score (BASDAI question 2) ≥ 4 (see Annex 6 for scoring criteria); Subjects who have been treated with non-steroidal anti-inflammatory drugs (NSAIDs) and still have active disease, or who have discontinued NSAIDs due to intolerance; defined as follows: subjects must have had at least 2 cumulative inadequate clinical responses to the recommended dose (≥2 weeks of each NSAID and ≥4 weeks of total use) or intolerance to at least 2 different oral NSAIDs. Intolerance defined as discontinuation of treatment with NSAIDs due to associated adverse events (e.g., allergic reactions, gastrointestinal signs or symptoms, etc.); Subjects taking treatment with NASIDs at the time of screening, requiring stable dose continuation for ≥ 2 weeks prior to randomization; no change in drug dose during the study period except for emergencies; if not taking, discontinuation for at least ≥ 2 weeks prior to randomization; If subjects are enrolled in the study on a combination of methotrexate (MTX), salazosulfapyridine (SASP) and/or hydroxychloroquine (HCQ), subjects must receive a stable dose of MTX (≤25 mg/week) and/or SASP (≤3 g/day) and/or HCQ (≤400 mg/day) for at least 28 days prior to the baseline visit. A maximum of two background csDMARDs allowed in combination; Subjects taking oral glucocorticoids at screening at doses ≤10 mg/day of prednisone (or equivalent doses of other glucocorticoids) that need to be continued for ≥4 weeks prior to randomization; if subjects are not taking oral glucocorticoids, they need to be off them for at least ≥4 weeks prior to randomization; The subject has received ≤ 1 prior treatment with a biologic agent prior to randomization. Subjects previously treated with biologic agents must have been off ≥ 6 half-lives prior to randomization. Exclusion Criteria: 1. Presence of the following diseases or history of disease: A known or suspected history of complete spinal ankylosis, or clinically and imaging confirmed complete spinal ankylosis; A history of any other autoimmune rheumatic disease; Patients with a combination of severe extra-articular manifestations, such as hyperthermia, interstitial pneumonia, pleurisy, pericarditis, severe vasculitis, or neurological pathology; Patients with current or recent serious, or progressive, or uncontrolled disease, including: hepatic, renal, hematologic, gastrointestinal, endocrine, metabolic, respiratory, cardiovascular, or neurologic disease; or patients who, in the opinion of the investigator, may affect patient safety or compliance;etc. 2.Any of the following laboratory test indicators are met at the time of the screening test: Those who test positive for the following bacteria or viruses at screening, such as HIV, syphilis, Hepatitis B Virus (HBSAg, HBeAg, Hepatitis B Virus-DNA, anyone positive for any of the three), Hepatitis C Virus (positive for anti-Hepatitis C Virus antibodies); If screening stage hepatitis B surface antigen negative (HBsAg-) and anti-hepatitis B core antibody positive (HBcAb+), additional quantitative Hepatitis B Virus-DNA test is required and excluded if quantitative > normal value; Routine blood count: white blood cell count (WBC) <3×109/L, absolute neutrophil count (ANC) <1.5×109/L, absolute lymphocyte count (ALC) <0.8×109/L, platelets (PLT) <100×109/L, hemoglobin (Hb) <100 g/L;etc. 3. Is taking or has a history of taking medication that: Those who are receiving any other csDMARDs or biologic DMARDs (except MTX, SASP, HCQ in the inclusion criteria) or other prohibited concomitant medications; if previous use of csDMARDs such as thalidomide, hydroxychloroquine or leflunomide, those who discontinued thalidomide, hydroxychloroquine, etc. for ≤ 4 weeks and leflunomide for ≤ 8 weeks prior to randomization (using criteria subjects not more than 28 days after Kauleenamine treatment or active carbon elution were not allowed to be enrolled in the trial); Those who have been treated with any tyrosine kinase (JAK) inhibitor (e.g. Tofacitinib, Baricitinib, Upadacitinib, etc.);etc. 4. Those who may be allergic to VC005, similar drugs or their excipients 5. Those with substance abuse or alcohol dependence 6. Subjects who, in the opinion of the investigator, may be at risk of gastrointestinal perforation during the course of the trial 7. Those who have participated in a clinical trial with any drug or device within 12 weeks prior to screening and have used that drug or device 8. Subjects who have a history of major surgery, joint surgery within 6 months prior to screening or who are scheduled to have surgery during the trial 9. Female patients who are planning to become pregnant or who are pregnant or breastfeeding, or who are unable to use effective contraception throughout the trial and for 3 months after the end of the trial (see Appendix 14 for details) 10. Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaojuan Lai
Phone
15358160458
Email
lai_xiaojuan@vcarepharmatech.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhanguo Li
Organizational Affiliation
Peking University People's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xu Liu
Organizational Affiliation
Peking University People's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peking University People's Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhanguo Li
Phone
13910713924
Email
Zgli99@aliyun.com

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

We'll reach out to this number within 24 hrs